The competition to develop next-generation diabetes treatments that not only provide cardiovascular and kidney protection like existing SGLT-2 inhibitors but also manage post-meal blood sugar levels is intensifying. In this context, Jeil Pharmaceutical has garnered attention by revealing the results of its Phase 2 clinical trial for the oral type 2 diabetes drug candidate JP-2266.
On July 30, Jeil Pharmaceutical announced that the results of the Phase 2 study for JP-2266 were published in the international journal 'Diabetes & Metabolism Journal (DMJ)'.
JP-2266 is a dual inhibitor that targets both SGLT-2, which inhibits glucose reabsorption in the kidneys, and SGLT-1, which delays glucose absorption in the intestines. It is being developed as a next-generation diabetes treatment that combines the benefits of existing SGLT-2 inhibitors with post-meal blood sugar control.
The clinical trial involved 156 patients with type 2 diabetes whose blood sugar levels were not adequately controlled by diet and exercise alone. Conducted across 28 medical institutions in South Korea, the study was randomized, double-blind, and placebo-controlled, with Professor Cha Bong-soo from Severance Hospital's Endocrinology Department serving as the trial coordinator.
According to the study results, JP-2266 significantly reduced hemoglobin A1c (HbA1c) levels compared to the placebo group after 12 weeks of administration. The estimated treatment difference (ETD) was a decrease of 0.94 percentage points in the 5 mg group and 0.97 percentage points in the 10 mg group, both achieving statistical significance.
The proportion of patients reaching an HbA1c level of less than 7% was 70.6% in the 10 mg group and 66.7% in the 5 mg group. Improvements were also observed in fasting blood sugar and post-meal blood sugar levels, with a reduction of approximately 63 to 68 mg/dL in post-meal blood sugar at the 12-week mark.
Weight loss and improvements in certain cardiovascular and metabolic risk factors were also confirmed. Notably, the 10 mg group showed a decrease in systolic blood pressure, along with improvements in insulin resistance and beta-cell function indicators. Safety assessments indicated that both doses had a similar incidence of adverse events as the placebo group, confirming overall good tolerability.
Professor Cha stated, "In Asian countries where carbohydrate intake is high, managing post-meal blood sugar is crucial, making JP-2266 a potentially significant treatment option. Further confirmation of its efficacy and safety is needed in Phase 3 trials."
Meanwhile, Jeil Pharmaceutical is accelerating the development of new drugs following the success of its potassium-competitive acid blocker (P-CAB) reflux disease treatment, 'Zacubo'. The company aims to shift its focus from introducing products to research and development (R&D), emphasizing a fundamental transformation in its approach.
On July 30, Jeil Pharmaceutical announced that the results of the Phase 2 study for JP-2266 were published in the international journal 'Diabetes & Metabolism Journal (DMJ)'.
JP-2266 is a dual inhibitor that targets both SGLT-2, which inhibits glucose reabsorption in the kidneys, and SGLT-1, which delays glucose absorption in the intestines. It is being developed as a next-generation diabetes treatment that combines the benefits of existing SGLT-2 inhibitors with post-meal blood sugar control.
The clinical trial involved 156 patients with type 2 diabetes whose blood sugar levels were not adequately controlled by diet and exercise alone. Conducted across 28 medical institutions in South Korea, the study was randomized, double-blind, and placebo-controlled, with Professor Cha Bong-soo from Severance Hospital's Endocrinology Department serving as the trial coordinator.
According to the study results, JP-2266 significantly reduced hemoglobin A1c (HbA1c) levels compared to the placebo group after 12 weeks of administration. The estimated treatment difference (ETD) was a decrease of 0.94 percentage points in the 5 mg group and 0.97 percentage points in the 10 mg group, both achieving statistical significance.
The proportion of patients reaching an HbA1c level of less than 7% was 70.6% in the 10 mg group and 66.7% in the 5 mg group. Improvements were also observed in fasting blood sugar and post-meal blood sugar levels, with a reduction of approximately 63 to 68 mg/dL in post-meal blood sugar at the 12-week mark.
Weight loss and improvements in certain cardiovascular and metabolic risk factors were also confirmed. Notably, the 10 mg group showed a decrease in systolic blood pressure, along with improvements in insulin resistance and beta-cell function indicators. Safety assessments indicated that both doses had a similar incidence of adverse events as the placebo group, confirming overall good tolerability.
Professor Cha stated, "In Asian countries where carbohydrate intake is high, managing post-meal blood sugar is crucial, making JP-2266 a potentially significant treatment option. Further confirmation of its efficacy and safety is needed in Phase 3 trials."
Meanwhile, Jeil Pharmaceutical is accelerating the development of new drugs following the success of its potassium-competitive acid blocker (P-CAB) reflux disease treatment, 'Zacubo'. The company aims to shift its focus from introducing products to research and development (R&D), emphasizing a fundamental transformation in its approach.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.